Assertio Therapeutics Valuation
| ASRT Stock | USD 11.62 0.23 1.94% |
At this time, the firm appears to be undervalued. Assertio Therapeutics shows a prevailing Real Value of $17.59 per share. The current price of the firm is $11.62. Our model approximates the value of Assertio Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.24, profit margin of (0.21) %, and Current Valuation of 22.6 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Assertio Therapeutics' valuation include:
Price Book 0.7193 | Enterprise Value | Enterprise Value Ebitda 4.9855 | Price Sales 0.5429 | Forward PE 15.8228 |
Undervalued
Today
Please note that Assertio Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Assertio Therapeutics is based on 3 months time horizon. Increasing Assertio Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Assertio Therapeutics' intrinsic value may or may not be the same as its current market price of 11.62, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.62 | Real 17.59 | Target 37.44 | Hype 11.63 | Naive 10.47 |
The intrinsic value of Assertio Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Assertio Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Assertio Therapeutics helps investors to forecast how Assertio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Assertio Therapeutics more accurately as focusing exclusively on Assertio Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Assertio Therapeutics' intrinsic value based on its ongoing forecasts of Assertio Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Assertio Therapeutics' closest peers.
Assertio Therapeutics Cash |
|
Assertio Revenue by Product
Assertio Therapeutics Total Value Analysis
Assertio Therapeutics is presently projected to have valuation of 22.6 M with market capitalization of 74.56 M, debt of 40.27 M, and cash on hands of 52.26 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Assertio Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
22.6 M | 74.56 M | 40.27 M | 52.26 M |
Assertio Therapeutics Investor Information
About 28.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.72. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.5. The entity recorded a loss per share of 4.5. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:15 split on the 26th of December 2025. Based on the key indicators related to Assertio Therapeutics' liquidity, profitability, solvency, and operating efficiency, Assertio Therapeutics may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter.Assertio Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Assertio Therapeutics has an asset utilization ratio of 43.89 percent. This implies that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Assertio Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Assertio Therapeutics Profitability Analysis
Based on Assertio Therapeutics' profitability indicators, Assertio Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Assertio Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 1997-03-31 | Previous Quarter -16.4 M | Current Value 11.4 M | Quarterly Volatility 38.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.3 | 0.79 |
|
|
For Assertio Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Assertio Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Assertio Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Assertio Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Assertio Therapeutics over time as well as its relative position and ranking within its peers.
Assertio Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Assertio Therapeutics is estimated to be -0.75 with future projections ranging from a low of -0.75 to a high of -0.75. Assertio Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -4.5. Please be aware that the consensus of earnings estimates for Assertio Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Assertio Therapeutics Earnings Estimation Breakdown
The calculation of Assertio Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Assertio Therapeutics is estimated to be -0.75 with the future projection ranging from a low of -0.75 to a high of -0.75. Please be aware that this consensus of annual earnings estimates for Assertio Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.75 Lowest | Expected EPS | -0.75 Highest |
Assertio Therapeutics Earnings Projection Consensus
Suppose the current estimates of Assertio Therapeutics' value are higher than the current market price of the Assertio Therapeutics stock. In this case, investors may conclude that Assertio Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Assertio Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 4 | 21.75% | 0.0 | -0.75 | -4.5 |
Assertio Therapeutics Ownership Allocation
The market capitalization of Assertio Therapeutics is $74.56 Million. Almost 69.05 percent of Assertio Therapeutics outstanding shares are held by general public with 2.49 (percent) owned by insiders and only 28.46 % by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Assertio Therapeutics Profitability Analysis
The company reported the previous year's revenue of 124.96 M. Net Loss for the year was (21.58 M) with profit before overhead, payroll, taxes, and interest of 89.93 M.About Assertio Therapeutics Valuation
The stock valuation mechanism determines Assertio Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Assertio Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Assertio Therapeutics. We calculate exposure to Assertio Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Assertio Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 98.6 M | 112.1 M | |
| Pretax Profit Margin | (0.17) | (0.16) | |
| Operating Profit Margin | (0.18) | (0.19) | |
| Net Loss | (0.17) | (0.16) | |
| Gross Profit Margin | 0.79 | 1.30 |
Assertio Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Assertio Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.4 M | |
| Quarterly Earnings Growth Y O Y | -0.188 | |
| Forward Price Earnings | 15.8228 |
Assertio Therapeutics Current Valuation Indicators
Assertio Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Assertio Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Assertio Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Assertio Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Assertio Therapeutics' worth.Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.